Details for Patent: 8,114,021
✉ Email this page to a colleague
Which drugs does patent 8,114,021 protect, and when does it expire?
Patent 8,114,021 protects ABILIFY MYCITE KIT and is included in one NDA.
This patent has sixty-three patent family members in nineteen countries.
Summary for Patent: 8,114,021
| Title: | Body-associated receiver and method |
| Abstract: | Receivers, which may be external or implantable, are provided. Aspects of receivers of the invention include the presence of one or more of: a high power-low power module; an intermediary module; a power supply module configured to activate and deactivate one or more power supplies to a high power processing block; a serial peripheral interface bus connecting master and slave blocks; and a multi-purpose connector. Receivers of the invention may be configured to receive a conductively transmitted signal. Also provided are systems that include the receivers, as well as methods of using the same. Additionally systems and methods are disclosed for using a receiver for coordinating with dosage delivery systems. |
| Inventor(s): | Robertson; Timothy (Belmont, CA), Omidvar; Fataneh (Danville, CA), Behzadi; Yashar (San Francisco, CA), Arne; Lawrence (Redwood City, CA), Rowberry; Kenneth (San Jose, CA), Hutchison; James (Palo Alto, CA), Leichner; Robert (Menlo Park, CA), Savage; George (Portola Valley, CA), Thompson; Andrew (Portola Valley, CA), Zdeblick; Mark (Portola Valley, CA), Kreidler; Marc (Sunnyvale, CA), Hafezi; Hooman (Redwood City, CA), Duck; Robert (San Francisco, CA) |
| Assignee: | Proteus Biomedical, Inc. (Redwood City, CA) |
| Application Number: | 12/673,326 |
|
Patent Claim Types: see list of patent claims | Delivery; Device; |
Drugs Protected by US Patent 8,114,021
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-001 | Nov 13, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-002 | Nov 13, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-003 | Nov 13, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,114,021
| PCT Information | |||
| PCT Filed | December 15, 2009 | PCT Application Number: | PCT/US2009/068128 |
| PCT Publication Date: | July 01, 2010 | PCT Publication Number: | WO2010/075115 |
International Family Members for US Patent 8,114,021
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009330321 | ⤷ Try a Trial | |||
| Australia | 2012284125 | ⤷ Try a Trial | |||
| Brazil | 112014001397 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
